AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33220141
Drug: Bonding agent
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonding agent (Adper™ Single Bond 2, 3M ESPE) applied before sealant application (Helioseal®clear, Ivoclar Vivadent)
Trial: 35449008
Drug: STRONG programme
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRONG programme (≥6 weekly sessions with patient education, motivational and pharmaceutical support)
Trial: 33780423
Drug: NeuroEPO (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroEPO (1 mL, at a concentration of 1 mg/mL) administered intranasally once a week for 5 weeks
Trial: 33780423
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intranasally once a week for 5 weeks
Trial: 33663737
Drug: Lower Dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower Dose Edoxaban Regimen (LDER) - 30 mg once daily (dose reduced to 15 mg in selective patients)
Trial: 33663737
Drug: Higher Dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Dose Edoxaban Regimen (HDER) - 60 mg once daily (dose reduced to 30 mg in selective patients)
Trial: 33663737
Drug: Lower Dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower Dose Edoxaban Regimen (LDER)
Trial: 33757440
Drug: Neoadjuvant FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant FOLFIRINOX chemotherapy (8 cycles) followed by surgery without adjuvant treatment (arm A)
Trial: 33757440
Drug: Neoadjuvant FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant FOLFIRINOX chemotherapy
Trial: 32899447
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1000 mg daily) during the first six weeks of training.
Trial: 32899447
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1000 mg daily) during the second six weeks of training.
Trial: 34500184
Drug: Additional mood-stabilizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional mood-stabilizing treatment
Trial: 36189646
Drug: Oral extended-release
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release nifedipine 30 mg every 24 hours
Trial: 34961950
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg twice daily
Trial: 34958123
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg b.i.d. enoxaparin
Trial: 34958123
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg o.d. enoxaparin
Trial: 32286883
Drug: Regular drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular drug-eluting stent
Trial: 36457363
Drug: Cognitive multisensory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive multisensory rehabilitation (CMR) for 6 weeks followed by 6 weeks of standard of care (no therapy) at home
Trial: 36457363
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (no therapy) for 6 weeks followed by 6 weeks of CMR
Trial: 32482335
Drug: sweet taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sweet taste moisturizing gel
Trial: 32482335
Drug: acid taste
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acid taste with Japanese apricot extract moisturizing gel
Trial: 32482335
Drug: Japanese apricot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese apricot scent moisturizing gel
Trial: 32482335
Drug: acid taste
RxNorm normalized name: 60 Second Taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acid taste with citric acid moisturizing gel
Trial: 32482335
Drug: tasteless and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasteless and odorless moisturizing gel
Trial: 32482335
Drug: control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (no gel administered)
Trial: 33639517
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point acupressure treatment (acupressure points with Cowherb seeds)
Trial: 33639517
Drug: Sham auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham auricular therapy (acupressure points without Cowherb seeds)
Trial: 33639517
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point acupressure treatment
Trial: 33639517
Drug: Sham auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham auricular therapy
Trial: 34215606
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) treatment, specific intervention details not provided.
Trial: 34208055
Drug: Epinephrine group
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine group (125 µg epinephrine)
Trial: 38241603
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy
Trial: 36259380
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg/day)
Trial: 32143721
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) 1950 mg with sublingual misoprostol 800 mcg
Trial: 32143721
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with sublingual misoprostol 800 mcg
Trial: 35980238
Drug: G Premio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G Premio Bond (GP; universal) with two coats
Trial: 35387686
Drug: Diet‐fish (hypocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet‐fish (hypocaloric diet + 3 g/day of omega‐3 supplementation)
Trial: 33992687
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline spray (control)
Trial: 36287566
Drug: Kisspeptin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kisspeptin administration (75-minute intravenous infusion of kisspeptin-54 at 1 nmol/kg/h)
Trial: 36029059
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/day for 22 weeks)
Trial: 33113526
Drug: 1,000 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 U/kg Epo intravenously for 6 doses, followed by 400 U/kg Epo subcutaneously 3 times a week through 32 weeks post-menstrual age
Trial: 36078778
Drug: General physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General physiotherapy for disease characteristics; control group treatment before discharge.
Trial: 34021703
Drug: ML-based scoring
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-based scoring functions
Trial: 35734895
Drug: Leucocyte‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte‐ and platelet‐rich fibrin (L‐PRF) application
Trial: 35734895
Drug: L‐PRF application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PRF application
Trial: 34299891
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily activity (Control)
Trial: 32414547
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin administered to the levator labii superioris alaeque nasi muscle (Group 1)
Trial: 32414547
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin administered to the orbicularis oris site (Group 2)
Trial: 39197976
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA)
Trial: 34760995
Drug: Fan therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fan therapy during 6-minute walk test (6MWT)
Trial: 34760995
Drug: No fan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fan therapy during 6-minute walk test (6MWT)
Trial: 35984123
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride injection (0.08 mg/kg)
Trial: 35987885
Drug: mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron 25 mg once per day for 12 weeks
Trial: 35987885
Drug: solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 5 mg once per day for 12 weeks
Trial: 33270306
Drug: Heparin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin without protamine reversal
Trial: 36170895
Drug: Pharmacist-led pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led pathway with 30% drug discount
Trial: 36170895
Drug: Pharmacist-led pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led pathway with 60% drug discount
Trial: 36170895
Drug: Pharmacist-led pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led pathway with 90% drug discount
Trial: 34578798
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with monosodium glutamate (MSG) at 2.7 g/day during the second round of chemotherapy
Trial: 35769355
Drug: Lobaplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin (30 mg/m²) added to docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Trial: 35769355
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Trial: 35769355
Drug: Lobaplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin (30 mg/m²) added to docetaxel and epirubicin.
Trial: 35769355
Drug: Lobaplatin added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lobaplatin added to chemotherapy.
Trial: 39669005
Drug: Intraarticular corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular corticosteroid injections
Trial: 33693494
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg SHR4640
Trial: 33693494
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg SHR4640
Trial: 33693494
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg benzbromarone
Trial: 616501576
Drug: Common three‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common three‐dose intramuscular priming series followed by a final booster at 6 months
Trial: 616501576
Drug: Common three‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common three‐dose intramuscular priming series followed by a final booster at 12 months
Trial: 616501576
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine regimens
Trial: 34824000
Drug: O2 treatment
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O2 treatment over the protective face mask
Trial: 35912143
Drug: Gamma globulin
RxNorm normalized name: Gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma globulin combined with azithromycin sequential therapy
Trial: 35912143
Drug: Azithromycin plus
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin plus comprehensive basic treatment
Trial: 34138667
Drug: IGF‐1 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐1 injections combined with HSR training
Trial: 34138667
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections combined with HSR training
Trial: 33583341
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 40 mg
Trial: 33933236
Drug: CT‐CONT (continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐CONT (continuation of first-line fluorouracil/platinum-based chemotherapy)
Trial: 33933236
Drug: CT‐DISC (discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT‐DISC (discontinuation of first-line chemotherapy)
Trial: 33336218
Drug: Gantenerumab 1200
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab 1200 mg every 4 weeks
Trial: 35094447
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.5% after TCA-CROSS
Trial: 35094447
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection before TCA-CROSS
Trial: 32513288
Drug: PK-guided dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided dosage adjustments of docetaxel-based chemotherapy
Trial: 32513288
Drug: BSA-guided dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSA-guided dosage adjustments of docetaxel-based chemotherapy
Trial: 35796651
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment plus GIP(3‐30)NH2
Trial: 33772963
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of antihaemophilic factor (recombinant)
Trial: 33772963
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion (BI) of antihaemophilic factor (recombinant)
Trial: 35768101
Drug: Whole-body photobiomodulation
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body photobiomodulation therapy (NovoTHOR)
Trial: 35088753
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg/d for 12 weeks)
Trial: 36331522
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg empagliflozin
Trial: 36331522
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg empagliflozin
Trial: 33086400
Drug: Emicizumab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 1.5 mg/kg once-weekly subcutaneous
Trial: 35543853
Drug: IVB +
RxNorm normalized name: Intravenous bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVB + vitamin D insufficient/deficient + oral vitamin D supplementation (Group 3)
Trial: 33227785
Drug: Panic-Focused Psychodynamic
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic-Focused Psychodynamic Therapy (PFPP)
Trial: 32985240
Drug: Maxillary protraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary protraction therapy in UCLP group
Trial: 32985240
Drug: Maxillary protraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary protraction therapy in noncleft group
Trial: 32985240
Drug: Maxillary protraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary protraction therapy in both groups
Trial: 32375104
Drug: Fulacimstat 25
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulacimstat 25 mg twice daily for 6 months
Trial: 35531757
Drug: Lidocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (20 mL of 2% solution)
Trial: 34749782
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy (MST), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Trial: 34749782
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral ultra-brief pulse width electroconvulsive therapy (RUL-UB-ECT), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Trial: 34656515
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy at 4 points with a diode laser at 810 nm wavelength, 6 J (100 mW, 60 seconds/point)
Trial: 35261590
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.375% bupivacaine
Trial: 35261590
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of 0.375% bupivacaine
Trial: 35261590
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.375% bupivacaine
Trial: 34256171
Drug: Endodontic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic therapy with MPQ, intracanal medication, and 2 applications of aPDT (0.005% methylene blue, 660 nm, 90 seconds)
Trial: 34256171
Drug: Endodontic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic Therapy with Mechanical Chemical Preparation (MPQ) and intracanal medication
Trial: 34543779
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of antiseizure medication (ASM)
Trial: 34543779
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of antiseizure medication (ASM)
Trial: 33874660
Drug: Metronidazole placement
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole placement into gingival pockets; General therapy with Calcemin
Trial: 33874660
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of metronidazole and Eplan; General therapy with alendronate and alphacalcidolum
Trial: 33874660
Drug: Eplan and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplan and alendronate and alphacalcidolum based medicines
Trial: 35141811
Drug: Clonazepam 0.5
RxNorm normalized name: clonazepam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 0.5 mg 30 min before bedtime for 4 weeks
Trial: 35141811
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin 2 mg 30 min before bedtime for 4 weeks
Trial: 34281467
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or ILI
Trial: 34655087
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg intravenously, maintained at 5 mg/kg/h)
Trial: 34655087
Drug: Low-dose remimazolam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remimazolam tosylate (0.25 mg/kg intravenously, maintained at 0.48 mg/kg/h)
Trial: 34655087
Drug: High-dose remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose remimazolam tosylate (0.25 mg/kg intravenously, maintained at 0.6 mg/kg/h)
Trial: 34655087
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate (both doses)
Trial: 32331026
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SPN-812
Trial: 32331026
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg SPN-812
Trial: 36105449
Drug: Mailuoning injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailuoning injection treatment
Trial: 35414566
Drug: HUG-5 tool
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HUG-5 tool administered periodically in an outpatient clinic using a semi-automated workflow
Trial: 32526771
Drug: Incremental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental oxygen uptake test on a treadmill before starting (neo-)adjuvant treatment and an exercise intervention
Trial: 37728450
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of bupivacaine with 75 mcg of clonidine
Trial: 37728450
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of bupivacaine